Page last updated: 2024-10-31

methocarbamol and Opioid-Related Disorders

methocarbamol has been researched along with Opioid-Related Disorders in 4 studies

Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.

Opioid-Related Disorders: Disorders related to or resulting from abuse or misuse of OPIOIDS.

Research Excerpts

ExcerptRelevanceReference
" Our aim is to assess the impact of adding methocarbamol on opioid use for patients undergoing primary ventral (umbilical and epigastric) hernia repair (PVHR) and inguinal hernia repair (IHR)."8.31Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair. ( Blackhurst, D; Carbonell, AM; Carbonell, C; Cobb, WS; Crosier, C; Desai, S; Hammond, B; Hoffman, K; Love, MW; Warren, JA, 2023)
" Our aim is to assess the impact of adding methocarbamol on opioid use for patients undergoing primary ventral (umbilical and epigastric) hernia repair (PVHR) and inguinal hernia repair (IHR)."4.31Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair. ( Blackhurst, D; Carbonell, AM; Carbonell, C; Cobb, WS; Crosier, C; Desai, S; Hammond, B; Hoffman, K; Love, MW; Warren, JA, 2023)
"Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)."1.72Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. ( Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Miano, TA1
Wang, L1
Leonard, CE1
Brensinger, CM1
Acton, EK1
Dawwas, GK1
Bilker, WB1
Soprano, SE1
Nguyen, TPP1
Woody, G1
Yu, E1
Neuman, M1
Li, L1
Hennessy, S1
Crosier, C2
Hammond, B2
Carbonell, C2
Hoffman, K2
Desai, S2
Blackhurst, D2
Carbonell, AM2
Love, MW2
Cobb, WS2
Warren, JA2
Ward, HB1
Barnett, BS1
Suzuki, J1

Other Studies

4 other studies available for methocarbamol and Opioid-Related Disorders

ArticleYear
Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
    Clinical pharmacology and therapeutics, 2022, Volume: 112, Issue:5

    Topics: Baclofen; Bayes Theorem; Benzodiazepines; Buprenorphine; Clonidine; Drug Interactions; Fluconazole;

2022
Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair.
    American journal of surgery, 2023, Volume: 226, Issue:6

    Topics: Analgesics, Opioid; Hernia, Inguinal; Herniorrhaphy; Humans; Methocarbamol; Opioid-Related Disorders

2023
Impact of methocarbamol on opioid use after ventral incisional hernia repair.
    American journal of surgery, 2023, Volume: 226, Issue:6

    Topics: Analgesics, Opioid; Hernia, Ventral; Herniorrhaphy; Humans; Incisional Hernia; Methocarbamol; Opioid

2023
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Substance abuse, 2019, Volume: 40, Issue:2

    Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug S

2019